Compare

Ambu A/S/DKr AMBU B

1D1W1M3M6MYTD1Y5YMAX

About Ambu A/S

Ambu A/S is a Danish company operating in the medical device industry, focusing on the development and marketing of products for hospitals and healthcare providers. The company specializes in anesthesiology, patient monitoring and diagnostics, and emergency care solutions. Some of Ambu's key products include single-use endoscopes, resuscitators, and electrodes for patient monitoring. Founded in 1937, Ambu is headquartered in Ballerup, Denmark, and serves a global market with a significant presence in Europe, North America, and Asia. The company is known for its strategic emphasis on innovation in single-use devices, which helps reduce the risk of cross-contamination and improves healthcare efficiency.
Ticker
DKr AMBU B
Sector
Health
Primary listing
CSE
Employees
5,200
Headquarters
Ballerup, Denmark
Website
www.ambu.com

Ambu A/S Metrics

BasicAdvanced
kr 21B
42.46
kr 1.92
1.39
kr 0.41
0.50%

Bulls say / Bears say

Endoscopy Solutions grew 16% organically in Q3, with Respiratory up 17.1% and Urology, ENT & GI up 15%; Ambu reported market-share gains across its endoscopy areas. This gives the company a strong growth engine. (Ambu A/S)
New clearances broaden Ambu’s opportunity: its GI scopes can now be used for both upper- and lower-GI procedures, nearly doubling the procedures they can target, while its bronchoscope portfolio has gained clearance for paediatric use. The GI expansion is planned for commercial launch in early 2027. (Ambu A/S, Ambu A/S)
Q3 EBIT margin rose to 13.5% from 11.3% a year earlier, while free cash flow increased to DKK 154m from DKK 128m. Tariff refunds helped the margin, but Ambu also reported better working capital and operating performance supporting cash generation. (Ambu A/S)
Ambu cut its full-year organic growth outlook to around 10% from 10–12%, following an earlier cut. Anesthesia & Patient Monitoring grew just 1.6% in Q3, and management expects very low single-digit growth for the year. (Ambu A/S)
The path to Ambu’s roughly 20% EBIT-margin ambition looks uncertain: UBS estimates a 15.7% margin by 2028 and says reaching the target would require more than 550 basis points of expansion in 2027–28. UBS also cut its earnings estimates after repeated resets. (Investing.com)
Competition is making ureteroscopy growth harder to capture. UBS cited a slow commercial ramp for Ambu’s ureteroscope and stronger pressure from Pusen and Verathon, and forecast slower Endoscopy Solutions growth than management’s target. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.

Funds containing Ambu A/S

Funds
Fund name
Fund size
DKr AMBU B weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.13%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.13%
iShares MSCI World Small Cap£WLDS
$9B0.02%
iShares MSCI World Small Cap$WSML
$9B0.02%
iShares MSCI World Small Cap€IUSN
$9B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.